IKT logo

Inhibikase Therapeutics (IKT)

Profile

Full Name

Inhibikase Therapeutics, Inc.

Ticker Symbol

IKT

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

December 23, 2020

Indexes

Not included

Website

http://www.inhibikase.com

Employees

15

Key Details

Price

$1.95(+2.37%)

Market cap

$144.59M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$1.16(+63.29% YoY)

PE ratio

-

Next earnings date

May 16, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.95
IKT price is $1.95

30-Day Relative Volume

0.83
IKT 30-day relative volume is 0.83

Price Performance

Price Today change

+2.37%
IKT price is up +2.37% today

Price YTD change

-40.15%
IKT price is down -40.15% since January 1st

Price 1-year change

-8.51%
IKT price is down -8.51% year-on-year

Price 3-year change

-74.48%
IKT price is down -74.48% over the past 3 years

Price Range

Price All-time high

$70.80
IKT price is currently -97.25% below its historical high of $70.80

Price 3-year low

$0.79
IKT price is currently +146.20% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$144.59M
IKT market capitalization is $144.59 million

Market cap 3-year change

+351.32%
IKT market capitalization is up +351.32% over the past 3 years

Market cap All-time high

$266.75M
IKT market capitalization is currently -45.80% below its historical high of $266.75 million

Market cap sector rank

53.04%
IKT market capitalization is higher than 53.04% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1047.81%
IKT shares outstanding is up +1047.81% year-on-year

Shares Outstanding 3-Year Change

+1668.14%
IKT shares outstanding is up +1668.14% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.17
IKT beta is 1.17

200-day SMA

$2.10
IKT price is currently -7.19% below its 200-day simple moving average

50-day SMA

$2.26
IKT price is currently -14.00% below its 50-day simple moving average

RSI

44.14
IKT 14-day relative strength index is 44.14

Volume

0.83
IKT 30-day relative volume is 0.83

ATR

$0.21
IKT average true range is $0.21

10-day Historical Volatility

126.22%
IKT 10-day historical volatility is 126.22%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
IKT annual revenue value is unknown

Revenue Analysts estimate

-
IKT annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
IKT annual revenue 1-year change is unknown

Revenue Sector rank

-
IKT annual revenue is unknown

EPS

EPS

-$1.16
IKT annual earnings per share is -$1.16

EPS Analysts estimate

-$0.45
IKT annual earnings per share is currently +155.90% higher than the consensus analysts' forecast

EPS 1-year change

+63.29%
IKT annual earnings per share is up +63.29% year-on-year

EPS Sector rank

52.78%
IKT annual earnings per share is higher than 52.78% of companies in Healthcare sector

Profit

Gross profit

-
IKT annual gross profit value is unknown

Gross margin

-
IKT annual gross profit margin value is unknown

Operating profit

-$28.59M
IKT annual operating income is -$28.59 million

Operating margin

-
IKT annual operating profit margin value is unknown

Net income

-$27.52M
IKT annual net profit is -$27.52 million

Net margin

-
IKT annual net profit margin value is unknown

Expenses

Total expenses

$28.59M
IKT annual total expenses is $28.59 million

Operating expenses

$28.59M
IKT annual total operating expenses is $28.59 million

Cost of goods sold

-
IKT annual cost of goods sold value is unknown

Selling, general & administrative expenses

$11.38M
IKT annual SGA is $11.38 million

Depreciation and amortization

$26.30K
IKT annual depreciation & amortization is $26.30 thousand

Interest expense

-
IKT annual interest expense value is unknown

Income tax

-
IKT annual income tax value is unknown

EBIT & EBITDA

EBIT

-$28.59M
IKT annual earnings before interest & taxes is -$28.59 million

EBITDA

-$28.56M
IKT annual EBITDA is -$28.56 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$98.60M
IKT annual total assets is $98.60 million

Non current assets

$148.50K
IKT annual long term assets is $148.50 thousand

Current assets

$98.45M
IKT annual total current assets is $98.45 million

Cash and cash equivalents

$56.49M
IKT annual cash & cash equivalents is $56.49 million

Accounts receivable

-
IKT annual accounts receivable value is unknown

Inventory

-
IKT annual inventory value is unknown

Liabilities

Total liabilities

$3.73M
IKT annual total liabilities is $3.73 million

Long term liabilities

$0.00
IKT annual total long term liabilities is $0.00

Current liabilities

$3.73M
IKT annual total current liabilities is $3.73 million

Accounts payable

$943.00K
IKT annual accounts payable is $943.00 thousand

Debt

Total debt

$110.50K
IKT annual total debt is $110.50 thousand

Total debt 1-year change

-54%
IKT annual total debt is down -54% year-on-year

Long term debt

$0.00
IKT annual long term debt is $0.00

Short term debt

$110.50K
IKT annual short term debt is $110.50 thousand

Equity & Capital

Shareholders equity

$94.87M
IKT annual stockholders equity is $94.87 million

Book value

$94.87M
IKT annual book value is $94.87 million

Retained earnings

-$94.42M
IKT annual retained earnings is -$94.42 million

Working capital

$94.72M
IKT annual working capital is $94.72 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$19.15M
IKT annual cash flow from operations is -$19.15 million

Cash from operations 1-year change

-5.88%
IKT annual cash flow from operations is down -5.88% year-on-year

Cash from investing

-$37.00M
IKT annual cash flow from investing activities is -$37.00 million

Cash from investing 1-year change

-417.45%
IKT annual cash flow from investing activities is down -417.45% year-on-year

Cash from financing

$103.48M
IKT annual cash flow from financing activities is $103.48 million

Cash from financing 1-year change

+1131.14%
IKT annual cash flow from financing activities is up +1131.14% year-on-year

CAPEX

CAPEX

-
IKT annual capital expenditures value is unknown

CAPEX 1-year change

-
IKT annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$19.15M
IKT annual free cash flow is -$19.15 million

Free cash flow 1-year change

-5.79%
IKT annual free cash flow is down -5.79% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
IKT annual gross profit margin value is unknown

Operating margin

-
IKT annual operating profit margin value is unknown

Net margin

-
IKT annual net profit margin value is unknown

ROA & ROE

ROA

-27.91%
IKT annual return on assets is -27.91%

ROE

-29.01%
IKT annual return on equity is -29.01%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
IKT price to earnings ratio value is unknown

PE ratio Sector rank

-
IKT price to earnings ratio is unknown

PB Ratio

PB ratio

1.52
IKT price to book ratio is 1.52

PB ratio Sector rank

56.71%
IKT price to book ratio is higher than 56.71% of companies in Healthcare sector

PS Ratio

PS ratio

-
IKT price to sales ratio value is unknown

PS ratio Sector rank

-
IKT price to sales ratio is unknown

Enterprise value

Enterprise value

$88.21M
IKT enterprise value is $88.21 million

Enterprise value Sector rank

48.64%
IKT enterprise value is higher than 48.64% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.09
IKT EV/EBITDA is -3.09

EV/EBITDA Sector rank

25.33%
IKT EV/EBITDA is higher than 25.33% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

26.37
IKT annual current ratio is 26.37

Quick ratio

-
IKT annual quick ratio value is unknown

Leverage

Debt to equity

0.00
IKT annual debt to equity ratio is 0.00

Interest coverage ratio

-
IKT annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
IKT piotroski f-score value is unknown

Altman Z-Score

-
IKT altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Mar 28, 25 HC Wainwright & Co.
Neutral
Feb 12, 25 HC Wainwright & Co.
Neutral
Nov 8, 24 Jefferies
Buy
Oct 14, 24 HC Wainwright & Co.
Buy
Aug 16, 24 HC Wainwright & Co.
Buy
May 21, 24 HC Wainwright & Co.
Buy
Mar 7, 24 HC Wainwright & Co.
Buy
Mar 5, 24 HC Wainwright & Co.
Buy
Aug 15, 23 HC Wainwright & Co.
Buy
Jun 30, 23 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

EUDA logo
EUDA Health Holdings Limited (EUDA)
DERM logo
Journey Medical (DERM)
FDMT logo
4D Molecular Therapeutics (FDMT)
MOLN logo
Molecular Partners AG (MOLN)
PROF logo
Profound Medical (PROF)
FENC logo
Fennec Pharmaceuticals (FENC)
CLLS logo
Cellectis SA (CLLS)
Baird Medical Investment Holdings Limited (BDMD)
PBYI logo
Puma Biotechnology (PBYI)
  • What is the ticker symbol for Inhibikase Therapeutics?
  • Does Inhibikase Therapeutics pay dividends?
  • What sector is Inhibikase Therapeutics in?
  • What industry is Inhibikase Therapeutics in?
  • What country is Inhibikase Therapeutics based in?
  • When did Inhibikase Therapeutics go public?
  • Is Inhibikase Therapeutics in the S&P 500?
  • Is Inhibikase Therapeutics in the NASDAQ 100?
  • Is Inhibikase Therapeutics in the Dow Jones?
  • When was Inhibikase Therapeutics's last earnings report?
  • When does Inhibikase Therapeutics report earnings?
  • Should I buy Inhibikase Therapeutics stock now?

What is the ticker symbol for Inhibikase Therapeutics?

The ticker symbol for Inhibikase Therapeutics is NASDAQ:IKT

Does Inhibikase Therapeutics pay dividends?

No, Inhibikase Therapeutics does not pay dividends

What sector is Inhibikase Therapeutics in?

Inhibikase Therapeutics is in the Healthcare sector

What industry is Inhibikase Therapeutics in?

Inhibikase Therapeutics is in the Biotechnology industry

What country is Inhibikase Therapeutics based in?

Inhibikase Therapeutics is headquartered in United States

When did Inhibikase Therapeutics go public?

Inhibikase Therapeutics's initial public offering (IPO) was on December 23, 2020

Is Inhibikase Therapeutics in the S&P 500?

No, Inhibikase Therapeutics is not included in the S&P 500 index

Is Inhibikase Therapeutics in the NASDAQ 100?

No, Inhibikase Therapeutics is not included in the NASDAQ 100 index

Is Inhibikase Therapeutics in the Dow Jones?

No, Inhibikase Therapeutics is not included in the Dow Jones index

When was Inhibikase Therapeutics's last earnings report?

Inhibikase Therapeutics's most recent earnings report was on Mar 27, 2025

When does Inhibikase Therapeutics report earnings?

The next expected earnings date for Inhibikase Therapeutics is May 16, 2025

Should I buy Inhibikase Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page